Fibrogen Inc., of San Francisco, and partner Astrazeneca plc, of London, said the Journal of the American Society of Nephrology published phase II data showing roxadustat, an investigational therapy for the treatment of anemia in patients with chronic kidney disease (CKD), achieved 96 percent hemoglobin (Hb) response and increased mean Hb regardless of baseline iron repletion status, C-reactive protein level, iron regimen or dialysis modality within seven weeks.